<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[ny publikation]]></title><description><![CDATA[<p dir="auto">Ny artikel i New England Journal of Medicine Om Semaglutide<br />
<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313917?query=TOC&amp;cid=NEJM%20eToc,%20April%2011,%202024%20DM2335507_NEJM_Non_Subscriber&amp;bid=-2077336432" rel="nofollow ugc">https://www.nejm.org/doi/full/10.1056/NEJMoa2313917?query=TOC&amp;cid=NEJM eToc, April 11, 2024 DM2335507_NEJM_Non_Subscriber&amp;bid=-2077336432</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/446355/ny-publikation</link><generator>RSS for Node</generator><lastBuildDate>Fri, 19 Jun 2026 10:37:20 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/446355.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 11 Apr 2024 11:25:25 GMT</pubDate><ttl>60</ttl></channel></rss>